ReviewTrends in molecular medicine2013
Microbiota impact on the epigenetic regulation of colorectal cancer.
Review in Trends in molecular medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 89 citations in OpenAlex.
- The impact of gut microbial short-chain fatty acids on colorectal cancer development and prevention.Gut microbes · 2025Review
- Sex differences in gut microbiota, hypertension, and cardiovascular risk.European journal of pharmacology · 2025Review
- The role of gut microbiome in colorectal cancer development: a comprehensive analysis based on metabolomics and immunomodulatory mechanisms.Frontiers in oncology · 2025Review
- Investigating the biological significance of the TCM principle "promoting urination to regulate bowel movements" through the influence of the intestinal microbiota and their metabolites on the renal-intestinal axis.Frontiers in cellular and infection microbiology · 2024Review
- Microbiota revolution: How gut microbes regulate our lives.World journal of gastroenterology · 2023Review
- Altered gut metabolites and microbiota interactions are implicated in colorectal carcinogenesis and can be non-invasive diagnostic biomarkers.Microbiome · 2022Article
- Genetic and epigenetic dependencies in colorectal cancer development.Gastroenterology report · 2022Review
- Review
- Novel Methylation Biomarkers for Colorectal Cancer Prognosis.Biomolecules · 2021Review
- Update and review of the gerodontology prospective for 2020's: Linking the interactions of oral (hypo)-functions to health vs. systemic diseases.Journal of dental sciences · 2021Review
- MicroRNAs overexpressed in Crohn's disease and their interactions with mechanisms of epigenetic regulation explain novel aspects of Crohn's disease pathogenesis.Clinical epigenetics · 2021Review
- Fecal Bacteria as Non-Invasive Biomarkers for Colorectal Adenocarcinoma.Frontiers in oncology · 2021Article
- Expression of Main Toll-Like Receptors in Patients with Different Types of Colorectal Polyps and Their Relationship with Gut Microbiota.International journal of molecular sciences · 2020Article
- Article
- Gut Microbiome and Osteoporosis.Aging and disease · 2020Review
- Transcriptomic signature of gut microbiome-contacting cells in colon of spontaneously hypertensive rats.Physiological genomics · 2020Article
- Gut Microbiota and Cancer of the Host: Colliding Interests.Advances in experimental medicine and biology · 2020Review
- Gut Bacteria and their Metabolites: Which One Is the Defendant for Colorectal Cancer?Microorganisms · 2019Review
- Influence of the microbiota on epigenetics in colorectal cancer.National science review · 2019Article
- Race, the microbiome and colorectal cancer.World journal of gastrointestinal oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Mechanisms of colorectal cancer (CRC) development can be generally divided into three categories: genetic, epigenetic, and aberrant immunologic signaling pathways, all of which may be triggered by an imbalanced intestinal microbiota. Aberrant gut microbial composition, termed 'dysbiosis', has been reported in inflammatory bowel disease patients who are at increased risk for CRC development. Recent studies indicate that it is feasible to rescue experimental models of colonic cancer by oral treatment with genetically engineered beneficial bacteria and/or their immune-regulating gene products. Here, we review the mechanisms of epigenetic modulation implicated in the development and progression of CRC, which may be the result of dysbiosis, and therefore may be amenable to therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.